Amgen Inc

24 de jun. de 2026, 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23 de jun. de 2026, 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22 de jun. de 2026, 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18 de jun. de 2026, 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17 de jun. de 2026, 19:53 UTC

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16 de jun. de 2026, 19:22 UTC

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15 de jun. de 2026, 21:09 UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12 de jun. de 2026, 19:51 UTC

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11 de jun. de 2026, 23:06 UTC

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10 de jun. de 2026, 23:51 UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9 de jun. de 2026, 19:56 UTC

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8 de jun. de 2026, 20:06 UTC

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5 de jun. de 2026, 23:01 UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.

4 de jun. de 2026, 23:51 UTC

Amgen will present at the Goldman Sachs Global Healthcare Conference on June 9, 2026. Shares are trading higher in after-market hours.

3 de jun. de 2026, 23:41 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and strong performance above its 20-day moving average.

2 de jun. de 2026, 23:02 UTC

Amgen Inc. shares are lower in after-market trading, continuing a trend of declines over the last three sessions and remaining below the 20-day moving average.

1 de jun. de 2026, 20:02 UTC

Amgen Inc. shares are lower today, dropping below Friday's close and nearing the lower end of their one-month trading range. No specific news was identified.

29 de mai. de 2026, 20:06 UTC

Amgen Inc's shares are higher today, reflecting a slight gain since Thursday's close. The stock remains stable within its one-month trading range.

28 de mai. de 2026, 23:56 UTC

Amgen Inc's shares are higher in after-market hours, maintaining stability above the 20-day moving average and within the one-month trading range.

27 de mai. de 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, influenced by broader market dynamics, including declining US Treasury yields and inflation concerns.

26 de mai. de 2026, 19:56 UTC

Amgen Inc. shares are lower as rising bond yields reflect inflationary pressures. Analysts maintain a positive outlook on the company's drug pipeline and capital allocation.

22 de mai. de 2026, 20:06 UTC

Amgen Inc. is trading higher amid scrutiny of its rare disease therapy, Tavneos, linked to patient deaths and regulatory restrictions on new prescriptions.

21 de mai. de 2026, 19:13 UTC

Amgen Inc shares rose after Japan allowed new prescriptions for a rare-disease drug, reversing a previous recommendation linked to reported deaths.

20 de mai. de 2026, 19:51 UTC

Amgen Inc. shares are higher following the appointment of Thomas Dittrich as CFO and strong revenue growth of 12.3% over the past two years.

19 de mai. de 2026, 20:03 UTC

Amgen Inc. shares are trading higher as analysts express optimism about revenue growth through 2027, despite a price target reduction to $427.

18 de mai. de 2026, 19:52 UTC

Amgen Inc shares are lower as safety concerns over Tavneos intensify. Kissei Pharmaceutical advised caution after reports of 20 deaths linked to the drug.

15 de mai. de 2026, 23:26 UTC

Amgen Inc shares are higher in after-market trading, despite social media concerns over recent decisions and a warning from Kissei Pharmaceutical regarding a rare drug.

14 de mai. de 2026, 19:16 UTC

Amgen shares are lower as Piper Sandler cuts price target to $427 from $432. The stock is trading within its one-month range.

13 de mai. de 2026, 23:02 UTC

Amgen Inc. shares are trading lower in after-market hours, following unusual activity earlier in the session and remaining below the 20-day moving average.